Baxter错过了收入和销售预测,损失更大,并削减了2026年的前景,刺激了14.6%的股票下跌。 Baxter missed earnings and sales forecasts, posted a larger loss, and cut 2026 outlook, spurring a 14.6% stock drop.

据报道,巴克斯特国际公司2025年第四季度的销售额为297亿美元,同比增长8%,但在运营基础上仅为3%,低于分析师的预期. Baxter International reported fourth-quarter 2025 sales of $2.97 billion, up 8% year-over-year but only 3% on an operational basis, missing analyst expectations. 由于差幅压力、税收增加和总差幅下降900基点,调整后的每股收入为4.44美元,低于预测的0.54美元。 Adjusted earnings per share were $0.44, below the $0.54 forecast, due to margin pressure, higher taxes, and a 900-basis-point drop in gross margin. 该公司净损失为11.2亿美元,比去年的5.12亿美元损失更加严重,肾脏护理部分现在被归类为停业。 The company posted a net loss of $1.12 billion, worsening from last year’s $512 million loss, with the Kidney Care segment now classified as discontinued. 尽管先进外科和医疗保健系统、药品和注射药物的增长有所下降。 Despite growth in Advanced Surgery and Healthcare Systems, Pharmaceuticals and Injectables declined. 巴克斯特(Baxter)发布了2026年薄弱的指南,预测销售增长率将稳定在1%,并调整EPS为1.85-2.05美元,低于市场2.25美元的估计数,导致其股票在市场前贸易中下跌14.6%。 Baxter issued weak 2026 guidance, projecting flat to 1% sales growth and adjusted EPS of $1.85–$2.05, below the market’s $2.25 estimate, causing its stock to fall 14.6% in pre-market trading.